143 related articles for article (PubMed ID: 11970981)
1. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols.
Palmowski MJ; Choi EM; Hermans IF; Gilbert SC; Chen JL; Gileadi U; Salio M; Van Pel A; Man S; Bonin E; Liljestrom P; Dunbar PR; Cerundolo V
J Immunol; 2002 May; 168(9):4391-8. PubMed ID: 11970981
[TBL] [Abstract][Full Text] [Related]
2. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
[TBL] [Abstract][Full Text] [Related]
3. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
[TBL] [Abstract][Full Text] [Related]
4. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients.
Palmowski M; Salio M; Dunbar RP; Cerundolo V
Immunol Rev; 2002 Oct; 188():155-63. PubMed ID: 12445289
[TBL] [Abstract][Full Text] [Related]
5. DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens.
Rice J; Dunn S; Piper K; Buchan SL; Moss PA; Stevenson FK
Cancer Res; 2006 May; 66(10):5436-42. PubMed ID: 16707472
[TBL] [Abstract][Full Text] [Related]
6. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
Rice J; Buchan S; Stevenson FK
J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
[TBL] [Abstract][Full Text] [Related]
7. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies.
Firat H; Garcia-Pons F; Tourdot S; Pascolo S; Scardino A; Garcia Z; Michel ML; Jack RW; Jung G; Kosmatopoulos K; Mateo L; Suhrbier A; Lemonnier FA; Langlade-Demoyen P
Eur J Immunol; 1999 Oct; 29(10):3112-21. PubMed ID: 10540322
[TBL] [Abstract][Full Text] [Related]
8. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
Song S; Wang F; He X; He Y; Li D; Sun S
Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
[TBL] [Abstract][Full Text] [Related]
10. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines.
Rice J; Elliott T; Buchan S; Stevenson FK
J Immunol; 2001 Aug; 167(3):1558-65. PubMed ID: 11466377
[TBL] [Abstract][Full Text] [Related]
11. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.
Valmori D; Lévy F; Miconnet I; Zajac P; Spagnoli GC; Rimoldi D; Liénard D; Cerundolo V; Cerottini JC; Romero P
J Immunol; 2000 Jan; 164(2):1125-31. PubMed ID: 10623865
[TBL] [Abstract][Full Text] [Related]
12. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
[TBL] [Abstract][Full Text] [Related]
13. Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization.
Loirat D; Lemonnier FA; Michel ML
J Immunol; 2000 Oct; 165(8):4748-55. PubMed ID: 11035120
[TBL] [Abstract][Full Text] [Related]
14. High avidity antigen-specific CTL identified by CD8-independent tetramer staining.
Choi EM; Chen JL; Wooldridge L; Salio M; Lissina A; Lissin N; Hermans IF; Silk JD; Mirza F; Palmowski MJ; Dunbar PR; Jakobsen BK; Sewell AK; Cerundolo V
J Immunol; 2003 Nov; 171(10):5116-23. PubMed ID: 14607910
[TBL] [Abstract][Full Text] [Related]
15. Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes.
Dadaglio G; Morel S; Bauche C; Moukrim Z; Lemonnier FA; Van Den Eynde BJ; Ladant D; Leclerc C
Int Immunol; 2003 Dec; 15(12):1423-30. PubMed ID: 14645151
[TBL] [Abstract][Full Text] [Related]
16. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
[TBL] [Abstract][Full Text] [Related]
17. Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo.
Iglesias MC; Mollier K; Beignon AS; Souque P; Adotevi O; Lemonnier F; Charneau P
Mol Ther; 2007 Jun; 15(6):1203-10. PubMed ID: 17375069
[TBL] [Abstract][Full Text] [Related]
18. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
[TBL] [Abstract][Full Text] [Related]
19. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
[TBL] [Abstract][Full Text] [Related]
20. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.
Qian J; Dong Y; Pang YY; Ibrahim R; Berzofsky JA; Schiller JT; Khleif SN
Int J Cancer; 2006 Jun; 118(12):3022-9. PubMed ID: 16425257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]